Skip to main content

Table 1 Characteristics of the Study Population

From: Clinical phenotyping in sarcoidosis using cluster analysis

Characteristic Missing: N (%) N = 5541
Gender
 Male 0 (0.0) 265 (47.8%)
 Female 289 (52.2%)
Race
 White 12 (2.2) 443 (81.7%)
 Black 90 (16.6%)
 Asian 4 (0.7%)
 American Indian 2 (0.4%)
 Other 3 (0.6%)
Smoking status
 Never smoker 2 (0.4) 367 (66.5%)
 Ever smoker 185 (33.5%)
Lungs 0 (0.0) 534 (96.4%)
Cardiac 0 (0.0) 71 (12.8%)
Skin 0 (0.0) 68 (12.3%)
Eye 0 (0.0) 58 (10.5%)
Calcium/Vit D Metabolism 0 (0.0) 54 (9.7%)
Liver 0 (0.0) 40 (7.2%)
Extrathoracic lymph nodes 0 (0.0) 35 (6.3%)
Bone-Joint 0 (0.0) 19 (3.4%)
Spleen 0 (0.0) 19 (3.4%)
Lofgren’s 0 (0.0) 17 (3.1%)
Other organs 0 (0.0) 17 (3.1%)
Neuro 0 (0.0) 14 (2.5%)
ENT 0 (0.0) 12 (2.2%)
Kidney 0 (0.0) 9 (1.6%)
Muscle 0 (0.0) 7 (1.3%)
Parotid salivary 0 (0.0) 5 (0.9%)
Bone marrow 0 (0.0) 5 (0.9%)
Extrapulmonary involvement 0 (0.0) 259 (46.8%)
Ever treatment 104 (18.8) 310 (68.9%)
Scadding stage
 0 44 (7.9) 102 (20.0%)
 1 67 (13.1%)
 2 183 (35.9%)
 3 86 (16.9%)
 4 72 (14.1%)
Number of organs involved
 0 0 (0.0) 10 (1.8%)
 1 303 (54.7%)
 2 149 (26.9%)
 3 53 (9.6%)
 4 24 (4.3%)
 5 14 (2.5%)
 6 1 (0.2%)
Mean number of organs 0 (0.0) 1.7 (1.0)
BMI 0 (0.0) 30.5 (6.8)
Age at diagnosis 1 (0.2) 46.6 (10.9)
Duration of Disease 1 (0.2) 6.0 (7.1)
FEV1/FVC 0 (0.0) 74.9 (9.8)
FVCpp 0 (0.0) 86.7 (16.8)
FEV1pp 0 (0.0) 83.2 (19.4)
  1. 1Data presented: n (%); mean (SD)